STALICLA will be leading computational drug repositioning in EU-funded project REPO4EU

STALICLA will play a key role in the consortium to build the Euro-Global Platform for Mechanism-based Drug Repurposing (REPO4EU), with an allocated budget of 1.7M to STALICLA Discovery and Data Science (DDS) unit.

REPO4EU consortium aims to address the urgent need to develop new cost-effective therapies as well as to improve existing treatments through international cooperation, pooling research and innovation expertise, and know-how worldwide. Among 13 proposals, REPO4EU is one of the two projects granted funding with around 22M , funded by EU (HORIZON-HLTH-DISEASE-2021-04-02) within the Key Strategic Orientation KSO-D ‘Creating a more resilient, inclusive and democratic European society’ of Horizon Europe’s Strategic Plan 2021-2024. STALICLA DDS, with a granted budget of 1.7M through the course of 6 years, will act as the work package leader for in silico drug repositioning. In this context, STALICLA DDS will use its know-how on systems biology and network endopharmacology to analyze biosamples and clinical data from hundreds of patients with neurodevelopmental disorders (NDDs).

It takes 15 years on average until a promising candidate compound reaches to the market. An intelligent strategy to facilitate the reduction of timeframes, decrease costs and improve the success rate of bringing drugs to the market is repurposing of already approved and/or investigational medicinal products beyond their original indication. In that regards, DDS will coordinate leveraging high quality genetic, molecular and clinical data assets and combine in silico systems biology and artificial intelligence (AI) approaches for drug repositioning. STALICLA will bring its unique know-how and expertise on multi-omics data-driven patient stratification and treatment matching for communicable and non-communicable diseases beyond NDDs.

Link to Consortium web and twitter

Link to the info on a funding call and info on the resolution of the call

About STALICLA

STALICLA SA is a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), with a first application in autism spectrum disorder (ASD). STALICLA is on a unique mission to identify clinically actionable patient subgroups and develop tailored treatments for those most impaired by their symptoms. Its DEPI technology is the first platform specifically developed to enable precision medicine in complex NDDs. The platform integrates comprehensive metabolomics, whole-genome sequencing, RNA sequencing and its advanced HC-Match module to pair patient biological signatures with drug candidates. DEPI has reached clinical proof of concept with its first pipeline candidate, STP1. STALICLA is advancing collaborative alliances with strategic third-party pipelines and is rapidly scaling its platform and clinical development activity.